You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》花旗降百濟神州(BGNE.US)目標價至275美元 內地反貪影響低於預期
花旗發表研報指,百濟神州(06160.HK)(BGNE.US)核心產品「澤布替尼」(Brukinsa)第三季度在美國的銷售額達到2.7億美元,符合預期,表現持續強勁,相信在美國血液學會年會上公布的ALPINE試驗三年隨訪數據,將有助於提升產品市場份額。 不過該行提醒,雖然澤布替尼在美國的市場滲透率較高,但管理層同時亦預計該產品在歐盟市場的上市速度會放緩,因為目前還處於上市初期,至於在中國市場份額目前則達約60%。 花旗認為,中國醫藥行業反貪腐行動對百濟神州的銷售額實際影響程度較預期小,期內中國銷售額僅按季減少約2%,但預期行動仍會持續至第四季,予「買入」評級,美股目標價由285美元降至275美元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account